After the pharmaceutical behemoth said that its fourth-quarter 2024 sales prediction of $13.5 billion missed earlier guidance by $400 million, Eli Lilly and Company ( LLY , Financials ) shares dropped 6.7% to $744.03 Tuesday at 1:47 p.m. ET.

With a 32% rise from the year before, the corporation still projects full-year 2024 income to be $45 billion. Notwithstanding robust sales of its incretin medicines Mounjaro and Zepbound, which generate $3.5 billion and $1.9 billion respectively, investors responded unfavorably to the reduced Q4 outlook.

Lilly gave hopeful income projections for 2025 ranging from $58 billion to $61 billion, therefore showing a midpoint rise of 32%. CEO David Ricks attributed the expectation to improved production capacity and new product introductions but highlighted slower-than-expected expansion in the U.S. incretin market as a factor influencing Q4 results.

In the first half of 2025, the company anticipates generating at least 60% more salable doses of incretins than in the same time in 2024, Ricks added.

The business intends to publish its Q4 2024 financial statements and further information on Feb. 6.

This article first appeared on GuruFocus .